Skip to content

A randomized controlled trial for the clinical effect of Wu-Mei-Wan Decoction in the treatment of primary hypertension with upper heat and lower cold syndrome

A randomized controlled trial for the clinical effect of Wu-Mei-Wan Decoction in the treatment of primary hypertension with upper heat and lower cold syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031117
Enrollment
Unknown
Registered
2020-03-22
Start date
2020-03-31
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Sponsors

Affiliated Hospital of Shandong University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients, who were diagnosed with the criteria of essential hypertension, who belonged to the types of upper heat and lower cold syndrome,who after the lifestyle intervention,and diagnosed the upper heat and lower cold syndrome of essential hypertension grade I; (2) In the past 2 weeks, the blood pressure was stable, without the treatment of traditional Chinese medicine or proprietary Chinese medicine, without the treatment of western medicine or after the treatment of western medicine, the blood pressure was still in hypertensive grade 1 patients; (3) aged 18-75 years old; (4) Volunteer to participate in the experiment and sign the informed consent, and cooperate with various investigations and tests.

Exclusion criteria

Exclusion criteria: 1. secondary hypertension, refractory hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure; 2. pregnant and lactating women, women of child-bearing age do not agree to use contraceptive measures during the experiment; 3. Have mental illness, can't cooperate very well; 4. confirmed to have serious heart disease, severe neurosis and heart, liver, kidney insufficiency; 5. With severe endocrine, hematopoietic system, liver, kidney and other primary diseases, malignant tumors, mental patients; 6. Uncorrected hyperthyroidism, hypothyroidism; Patients with nephrotic syndrome, diabetes mellitus and acute hepatobiliary disease; 7. people who have suffered from serious cerebrovascular accidents, heart diseases, severe trauma, major surgery and other primary diseases with unstable general conditions and poor prognosis within 6 months; 8. Data were collected on cases of other diseases that were under medical treatment and affected experimental drug observers; 9. those who have participated in clinical trials of other drugs within three months; 10. Other conditions that the researchers considered inappropriate for inclusion were eliminated.

Design outcomes

Primary

MeasureTime frame
Mean dynamic blood pressure;symptom score of TCM;Quality of life score;NOS3, TNF, IL6, TP53, CCL2;

Secondary

MeasureTime frame
Blood sugar;triglycerides;triglycerides;HDL-C;LDL-C;Liver function;Renal function;Routine blood;Routine urine;Routine stool;ECG;

Countries

China

Contacts

Public ContactWu Bo

Affiliated Hospital of Shandong University of TCM

wubojinan@163.com+86 18660199889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026